FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4322775340> ?p ?o ?g. }

• W4322775340 endingPage "03" @default.
• W4322775340 startingPage "PD14" @default.
• W4322775340 abstract "Abstract Background: Fanconi Anemia (FA) proteins facilitate homologous recombination (HR)-mediated repair of DNA interstrand cross-links. Germline monoallelic, pathogenic/likely pathogenic (P/LP) variants in the highly-penetrant (HP) breast cancer (BC) FA genes, BRCA1 (FANCS), BRCA2 (FANCD1) and PALB2 (FANCN)), compromise HR and predispose to hereditary BC. The effects of monoallelic, pathogenic variants in other non-HP BC FA genes upon HR and BC predisposition remain less understood. In this investigation we report the germline mutational landscape of FA gene P/LP variants and somatic molecular consequences of patients with BC diagnoses from City of Hope’s (COH) INSPIRE (Implementing Next-generation Sequencing for Precision Intervention and Risk Evaluation) study. Methods: COH-INSPIRE is a universal access study open to all patients at COH with a personal and/or family history of cancer. Patients undergo custom panel-based germline genetic testing to detect P/LP single nucleotide variants (SNVs), short insertions/deletions (indels) and exon-level deletions/duplications in 155 cancer-predisposition genes including the HP BC FA genes and 15 non-HP BC FA genes [FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCJ (BRIP1), FANCL, FANCM, FANCO (RAD51C), FANCP (SLX4), FANCQ (ERCC4) and FANCU (XRCC2)]. Patients’ tumor specimens undergo somatic tumor (&gt;400X)-normal (&gt;180X) whole exome and transcriptome sequencing (&gt;50 million reads). Somatic sequencing identifies P/LP SNVs, indels, copy number events, and fusions. Secondary analyses assessed somatic homologous recombination deficiency (HRD) by examining tumor mutational signatures, as well as an ensemble HRD score derived by combining individual genomic loss of heterozygosity, telomeric allelic imbalance and large-scale molecular transition scores. Reference comparison of germline and somatic features to current FDA therapeutic guidelines and NIH clinical trials registrations determined eligibility for precision therapeutic intervention and clinical trial enrollment. Results: Of 7,584 patients enrolled in COH-INSPIRE, 1,651 (21.8%) patients had a BC diagnosis. Germline panel testing of BC patients identified 204 (12.4%) with germline P/LP variant in a FA gene. Greater than one third of FA gene-altered BC patients (37.7%) carried a P/LP variant in a non-HP BC FA gene. We observed that BC patients with a non-HP BC FA gene variant may demonstrate HR compromise as evidenced by presence of a Signature 3 mutational profile or an elevated combined HRD score (&gt; 33 and/or &gt; 42). (Table 1) Further, we identified ostensible segregation of triple negative BC in a family harboring a germline pathogenic variant in FANCG. With regard to precision clinical actionability (i.e. qualification for targeted therapeutic intervention [PARP inhibitor (PARPi)] and/or clinical trial) for patients with advanced stage BC: All patients with germline P/LP HP BC FA gene variant and 20.7% (N=16) of patients with a P/LP FA non-HPBC FA gene variant met criteria for treatment with on/off-label PARPi. 100% of patients with advanced BC with germline P/LP HP BC or non-HPBC FA gene variant qualified for a clinical trial. Conclusions: Patients with BC often carry a germline monoallelic, P/LP FA gene variant; in more than one third, the FA gene alteration occurs in a non-HP BC FA gene. BC patients harboring a monoallelic germline non-HP BC P/LP FA gene may exhibit somatic mutational signatures and HRD scoring consistent with compromise of HR. Somatic tumor evaluation of BC patients with germline P/LP non-HP BC FA gene variants expands opportunities for precision therapeutic intervention and clinical trial enrollment. Continued appraisal will clarify emerging questions of germline non-HP P/LP FA gene-associated autosomal dominant BC risk and management as well as facilitate optimization of precision BC care. Table 1 Summary Molecular Features of BC patients with P/LP Variants in FA gene from COH-INSPIRE Citation Format: Laura Kruper, Kevin McDonnell, Joseph Bonner, Kevin K. Tsang, Veronica Jones, Joanne Mortimer, Sidney S. Lindsey, Ilana Solomon, Heather Hampel, Wai Park, Gregory E. Idos, Stacy Gray, Stephen Gruber. PD14-03 Reappraising the Fanconi Anemia DNA repair pathway in breast cancer risk and precision intervention: Insights and opportunities from the City of Hope INSPIRE study [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2023;83(5 Suppl):Abstract nr PD14-03." @default.
• W4322775340 created "2023-03-03" @default.
• W4322775340 creator A5003819100 @default.
• W4322775340 creator A5005344580 @default.
• W4322775340 creator A5012798070 @default.
• W4322775340 creator A5013284308 @default.
• W4322775340 creator A5031398136 @default.
• W4322775340 creator A5031678728 @default.
• W4322775340 creator A5042231024 @default.
• W4322775340 creator A5048807628 @default.
• W4322775340 creator A5051463129 @default.
• W4322775340 creator A5062321082 @default.
• W4322775340 creator A5070083610 @default.
• W4322775340 creator A5070703103 @default.
• W4322775340 creator A5079121091 @default.
• W4322775340 date "2023-03-01" @default.
• W4322775340 modified "2023-10-16" @default.
• W4322775340 title "Abstract PD14-03: PD14-03 Reappraising the Fanconi Anemia DNA repair pathway in breast cancer risk and precision intervention: Insights and opportunities from the City of Hope INSPIRE study" @default.
• W4322775340 doi "https://doi.org/10.1158/1538-7445.sabcs22-pd14-03" @default.
• W4322775340 hasPublicationYear "2023" @default.
• W4322775340 type Work @default.
• W4322775340 citedByCount "0" @default.
• W4322775340 crossrefType "journal-article" @default.
• W4322775340 hasAuthorship W4322775340A5003819100 @default.
• W4322775340 hasAuthorship W4322775340A5005344580 @default.
• W4322775340 hasAuthorship W4322775340A5012798070 @default.
• W4322775340 hasAuthorship W4322775340A5013284308 @default.
• W4322775340 hasAuthorship W4322775340A5031398136 @default.
• W4322775340 hasAuthorship W4322775340A5031678728 @default.
• W4322775340 hasAuthorship W4322775340A5042231024 @default.
• W4322775340 hasAuthorship W4322775340A5048807628 @default.
• W4322775340 hasAuthorship W4322775340A5051463129 @default.
• W4322775340 hasAuthorship W4322775340A5062321082 @default.
• W4322775340 hasAuthorship W4322775340A5070083610 @default.
• W4322775340 hasAuthorship W4322775340A5070703103 @default.
• W4322775340 hasAuthorship W4322775340A5079121091 @default.
• W4322775340 hasConcept C102744134 @default.
• W4322775340 hasConcept C104317684 @default.
• W4322775340 hasConcept C109825262 @default.
• W4322775340 hasConcept C111425858 @default.
• W4322775340 hasConcept C119054055 @default.
• W4322775340 hasConcept C134935766 @default.
• W4322775340 hasConcept C13514818 @default.
• W4322775340 hasConcept C135763542 @default.
• W4322775340 hasConcept C153209595 @default.
• W4322775340 hasConcept C2776071976 @default.
• W4322775340 hasConcept C2776653068 @default.
• W4322775340 hasConcept C2778124228 @default.
• W4322775340 hasConcept C2778144015 @default.
• W4322775340 hasConcept C2778993383 @default.
• W4322775340 hasConcept C2909462720 @default.
• W4322775340 hasConcept C501734568 @default.
• W4322775340 hasConcept C502942594 @default.
• W4322775340 hasConcept C54355233 @default.
• W4322775340 hasConcept C60748783 @default.
• W4322775340 hasConcept C86803240 @default.
• W4322775340 hasConceptScore W4322775340C102744134 @default.
• W4322775340 hasConceptScore W4322775340C104317684 @default.
• W4322775340 hasConceptScore W4322775340C109825262 @default.
• W4322775340 hasConceptScore W4322775340C111425858 @default.
• W4322775340 hasConceptScore W4322775340C119054055 @default.
• W4322775340 hasConceptScore W4322775340C134935766 @default.
• W4322775340 hasConceptScore W4322775340C13514818 @default.
• W4322775340 hasConceptScore W4322775340C135763542 @default.
• W4322775340 hasConceptScore W4322775340C153209595 @default.
• W4322775340 hasConceptScore W4322775340C2776071976 @default.
• W4322775340 hasConceptScore W4322775340C2776653068 @default.
• W4322775340 hasConceptScore W4322775340C2778124228 @default.
• W4322775340 hasConceptScore W4322775340C2778144015 @default.
• W4322775340 hasConceptScore W4322775340C2778993383 @default.
• W4322775340 hasConceptScore W4322775340C2909462720 @default.
• W4322775340 hasConceptScore W4322775340C501734568 @default.
• W4322775340 hasConceptScore W4322775340C502942594 @default.
• W4322775340 hasConceptScore W4322775340C54355233 @default.
• W4322775340 hasConceptScore W4322775340C60748783 @default.
• W4322775340 hasConceptScore W4322775340C86803240 @default.
• W4322775340 hasIssue "5_Supplement" @default.
• W4322775340 hasLocation W43227753401 @default.
• W4322775340 hasOpenAccess W4322775340 @default.
• W4322775340 hasPrimaryLocation W43227753401 @default.
• W4322775340 hasRelatedWork W3001432273 @default.
• W4322775340 hasRelatedWork W3013492213 @default.
• W4322775340 hasRelatedWork W3088221514 @default.
• W4322775340 hasRelatedWork W4282965106 @default.
• W4322775340 hasRelatedWork W4292065534 @default.
• W4322775340 hasRelatedWork W4313648097 @default.
• W4322775340 hasRelatedWork W4322775340 @default.
• W4322775340 hasRelatedWork W4322775472 @default.
• W4322775340 hasRelatedWork W4361957646 @default.
• W4322775340 hasRelatedWork W4361959755 @default.
• W4322775340 hasVolume "83" @default.
• W4322775340 isParatext "false" @default.
• W4322775340 isRetracted "false" @default.
• W4322775340 workType "article" @default.